We are live on ! Find out more
LENZ

LENZ Therapeutics
LENZ

63 hedge funds and large institutions have $186M invested in LENZ Therapeutics in 2022 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 22 increasing their positions, 14 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 6

57% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 14

9% more funds holding

Funds holding: 58 → 63 (+5)

0.42% more ownership

Funds ownership: 8.54% → 8.96% (+0.42%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

57% less capital invested

Capital invested by funds: $432M → $186M (-$246M)

Holders
63
Holders Change
+5
Holders Change %
+8.62%
% of All Funds
0.99%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
11
Increased
22
Reduced
14
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$8.87M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$4.7M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$4.49M
4
BlackRock
BlackRock
New York
+$4.31M
5
EC
EcoR1 Capital
California
+$3M

Top Sellers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
-$8.24M
2
LGM
Logos Global Management
California
-$5.05M
3
PA
Perceptive Advisors
New York
-$4.69M
4
RSCM
Rock Springs Capital Management
Maryland
-$2.58M
5
Morgan Stanley
Morgan Stanley
New York
-$1.21M
Name Holding Trade Value Shares
Change 		Change in
Stake
AB
51
Amalgamated Bank
New York
$21K +$37.3K +597 New
AF
52
Amalgamated Financial
New York
$21K +$37.3K +597 New
TRCT
53
Tower Research Capital (TRC)
New York
$14K -$28.5K -455 -53%
Legal & General Group
54
Legal & General Group
United Kingdom
$14K +$11.7K +187 +86%
MLICM
55
Metropolitan Life Insurance Company (MetLife)
New York
$12K +$21.1K +337 New
Citigroup
56
Citigroup
New York
$12K -$30.5K -488 -59%
Royal Bank of Canada
57
Royal Bank of Canada
Ontario, Canada
$9K -$12.1K -193 -43%
Osaic Holdings
58
Osaic Holdings
Arizona
$7K – – –
AIP
59
Ameritas Investment Partners
Nebraska
$6K – – –
PHK
60
Point72 Hong Kong
Hong Kong
$5K +$9.2K +147 New
APA
61
American Portfolios Advisors
New York
$1.38K – – –
FDCDDQ
62
Federation des caisses Desjardins du Quebec
Quebec, Canada
$1.02K – – –
Daiwa Securities Group
63
Daiwa Securities Group
Japan
$1K – – –
SFM
64
Sphera Funds Management
Israel
– -$8.24M -94,742 Closed
LGM
65
Logos Global Management
California
– -$5.05M -58,044 Closed
E
66
Ergoteles
New York
– -$897K -10,308 Closed
Jane Street
67
Jane Street
New York
– -$520K -5,980 Closed
JG
68
Jefferies Group
New York
– -$374K -4,296 Closed
CAN
69
Cetera Advisor Networks
California
– -$179K -2,057 Closed
1 2
3

LENZ Hedge Fund Activity: Q1 2022 in Review

63 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q1 2022, worth a combined $186M — down 57% from $432M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new LENZ positions and 6 closed out — a net gain of 5 holders — while 22 added to existing stakes and 14 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $8.87M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $8.24M sold.

  • 63 institutional investors held LENZ Therapeutics (LENZ) as of Q1 2022, up from 58 in Q4 2021.
  • Funds reported $186M of LENZ Therapeutics stock for Q1 2022, down 57% quarter-over-quarter.
  • 11 funds opened new LENZ Therapeutics positions in Q1 2022 and 6 closed out, a net change of +5 holders.
  • The largest LENZ Therapeutics buyer in Q1 2022 was Fidelity Investments, an estimated $8.87M added.
  • The largest LENZ Therapeutics seller in Q1 2022 was Sphera Funds Management, an estimated $8.24M sold.

Based on aggregated 13F filings for Q1 2022.